Drug
IL-1Ra
IL-1Ra is a pharmaceutical drug with 5 clinical trials. Historical success rate of 66.7%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_1
2
40%
Ph phase_3
1
20%
Ph phase_2
1
20%
Ph not_applicable
1
20%
Phase Distribution
2
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(2)
Terminated(1)
Other(2)
Detailed Status
unknown2
Completed2
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (40.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)
N/A1 (20.0%)
Trials by Status
terminated120%
unknown240%
completed240%
Recent Activity
0 active trials
Showing 5 of 5
unknownphase_3
SC IL-1Ra in SAH - Phase III Trial (SCIL)
NCT03249207
unknownphase_1
Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects
NCT03383276
terminatedphase_1
Topical IL-1-Ra for Treatment of Corneal Neovascularization
NCT00915590
completednot_applicable
Role of Interleukin-1 in the Regulation of Muscle Derived Interleukin-6 During Exercise
NCT01771445
completedphase_2
Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist
NCT00303394
Clinical Trials (5)
Showing 5 of 5 trials
NCT03249207Phase 3
SC IL-1Ra in SAH - Phase III Trial (SCIL)
NCT03383276Phase 1
Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects
NCT00915590Phase 1
Topical IL-1-Ra for Treatment of Corneal Neovascularization
NCT01771445Not Applicable
Role of Interleukin-1 in the Regulation of Muscle Derived Interleukin-6 During Exercise
NCT00303394Phase 2
Treatment of Patients With Type 2 Diabetes With an Interleukin-1 Antagonist
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5